Jefferies Group Weighs in on H. Lundbeck A/S-‘s Q1 2018 Earnings (HLUYY)

H. Lundbeck A/S- (OTCMKTS:HLUYY) – Stock analysts at Jefferies Group issued their Q1 2018 earnings estimates for shares of H. Lundbeck A/S- in a research note issued to investors on Thursday. Jefferies Group analyst P. Welford anticipates that the company will post earnings of $0.81 per share for the quarter. Jefferies Group also issued estimates for H. Lundbeck A/S-‘s Q2 2018 earnings at $0.76 EPS, Q3 2018 earnings at $0.79 EPS, Q4 2018 earnings at $0.84 EPS, FY2018 earnings at $3.20 EPS, FY2019 earnings at $3.24 EPS, FY2020 earnings at $3.54 EPS and FY2022 earnings at $3.08 EPS.

H. Lundbeck A/S- (OTCMKTS:HLUYY) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.73 EPS for the quarter. H. Lundbeck A/S- had a return on equity of 30.48% and a net margin of 15.07%.

Separately, Zacks Investment Research raised H. Lundbeck A/S- from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Friday, December 15th.

H. Lundbeck A/S- (OTCMKTS HLUYY) opened at $49.98 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.36 and a quick ratio of 1.13. The company has a market capitalization of $9,476.67, a price-to-earnings ratio of 25.49, a price-to-earnings-growth ratio of 1.24 and a beta of 0.09. H. Lundbeck A/S- has a one year low of $40.70 and a one year high of $66.67.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2018/02/10/jefferies-group-weighs-in-on-h-lundbeck-a-s-s-q1-2018-earnings-hluyy.html.

H. Lundbeck A/S- Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply